Topiramate Tablet, Film Coated
Product Images NDC 43063-997

4 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 43063-997). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063997 Label (43063997)

43063997 Label (43063997)
Label for Topiramate USP 50 MG oral film-coated tablets by PD-Rx Pharmaceuticals, Inc. The label shows 30 tablets per package with NDC 43063-997-30 and includes reorder number 110845, lot number G20D20, and expiration date 07/2022. The label also contains barcodes, a warning to keep out of reach of children, and a dosage instruction placeholder.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure diagram of Topiramate, showing its molecular framework with various oxygen, sulfur, nitrogen, carbon, and hydrogen atoms connected in a specific arrangement.*
FDA Label Image

Figure-1jpg (Figure 1)

Figure-1jpg (Figure 1)
A line graph showing cumulative rates for time to first seizure over 500 days for two groups of patients taking Topiramate: 50 mg/day and 400 mg/day. The x-axis represents time in days, and the y-axis shows cumulative rates. The graph compares seizure occurrence between the two dosage groups with a noted p-value of 0.0002, indicating statistical data related to the treatments.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar chart showing the change from baseline to double-blind phase in average monthly migraine period rate with Topiramate treatment at doses of 50 mg/day, 100 mg/day, and 200 mg/day compared to placebo. Results from two studies (Study 11 and Study 12) are displayed with significance markers for 100 mg/day and 200 mg/day doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.